A biopolymer is disclosed that comprises a polydeoxyribonucleotide (PDRN), or a derivative or modification thereof, having a molecular weight in the range of 400 kDa to 3200 kDa, and an anionic and ampholytic heteropolysaccharide having sulfate and carboxyl groups and a molecular weight in the range of 14 MDa and 16 MDa, in which the polydeoxyribonucleotide and the heteropolysaccharide are crosslinked by genipin or an analogue or derivative thereof. Furthermore, the invention relates to methods of producing such biopolymer and uses thereof.

A medical device, the medical device including a substrate defining a surface; a plasma polymer layer bound to and coating the surface; and a bactericide layer bound to the plasma polymer layer, the plasma polymer layer being between the substrate and the bactericide layer. Also, a method for coating a surface of a substrate of a medical device with a bactericide layer, the method including: exposing the surface to a plasma to form a plasma polymer layer bound to the surface; and binding a bactericide layer to the plasma polymer layer.

Cardiovascular prostheses that include an ECM-mimicking composition, which is adapted to induce modulated healing of damaged or diseased cardiovascular tissue and, thereby, associated structures, when administered thereto. The ECM-mimicking composition includes a polymer component and a pharmacological component. The polymer component includes poly(glycerol sebacate) (PGS). The pharmacological component includes a corticosteroid. The ECM-mimicking composition can also include a biological component having a biologically active agent, such as an exosome, a cytokine and a growth factor.

Provided are liposomes that encapsulate adenosine. The liposomes may be formed from sphingomyelin or a combination of sphingomyelin and 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) or a combination of sphingomyelin and 1,2-dimyristoyl-sn-glycero-3-phosphorylglycerol (DMPG) or a combination of sphingomyelin, DMPG, and DMPC. The liposomes encapsulating adenosine may be used to induce cartilage regeneration, treat osteoarthritis, alleviate joint pain, and/or slow, arrest, and/or reverse progressive structural tissue damage associated with osteoarthritis or treat osteoarthritis, rheumatoid arthritis, acute gouty arthritis, and/or synovitis. The liposomes may release adenosine for up to two weeks.

One aspect of the invention provides a method of treating a chronic wound including administering to the wound at least one agent from a delivery system wherein the agent induces sequential conversion of a first population of wound macrophages in the wound to M2A macrophages and a second population of wound macrophages to M2C macrophages. The sequential conversion of the wound macrophages promotes tissue remodeling.

Provided is an implant material, an implant suitable for implantation in bone defect repair and in spinal fusion, and a preparation method thereof. The implant material is used for filling in an internal cavity of a titanium cage/titanium stent (10) or a bone defect site, and is consisted of an upper layer (21), a lower layer (22) and an intermediate layer between the upper layer (21) and lower layer (22), wherein the intermediate layer is composed of an annular coating region (23) located at the periphery and a central region (24) located inside the annular coating region. The central region (24) is filled with a first filling material, which is a gel material having a pro-osteogenic effect. The annular coating region (23) is filled with a second filling material, which is a gel material regulating epigenetics. The upper layer (21) and lower layer (22) are filled with a third filling material, which is a gel material regulating immuno-inflammatory response and stress response. The implant of the present disclosure can adapt to the microenvironment of different regions of the injury sites and orderly regulate the repair process, and is suitable for implantation in bone defect repair and spinal fusion.

Methods and compositions for reducing a ratio of collagen III to collagen I in wounded skin, treating wounds and accelerating healing is provided with a surfactant polymer dressing comprising FL2 siRNA, collagen and a poloxamer.

Cardiovascular prostheses for treating, reconstructing and replacing damaged or diseased cardiovascular tissue. The prostheses are in the form of sheet structures that are formed from a composition that includes adolescent mammalian dermal tissue and a plurality of exogenously added exosomes. In some instances, the composition also includes at least one exogenously added cell, such as an embryonic stem cell, a mesenchymal stem cell and a hematopoietic stem cell. The prostheses are adapted to induce neovascularization, stem cell proliferation and, thereby, remodeling of damaged biological tissue and regeneration of new biological tissue and structures, when the prostheses are delivered to the damaged biological tissue.

A therapeutic microporous hydrogel scaffold for use in an animal is disclosed that releases one or more therapeutic agents or drugs. The scaffold uses a drug-releasing microporous annealed particle system that encapsulates drug-loaded nanoparticles into particle building blocks. By modulating nanoparticle hydrophilicity and pre-gel solution viscosity, the particle building blocks were generated with consistent and homogeneous encapsulation of nanoparticles. The scaffold may be used to treat myocardial infarction (MI) using, for example, the drugs forskolin (F) and Repsox (R). The intramyocardial injection of the pre-annealed hydrogel slurry of particles that formed the resultant scaffold improved left ventricular functions, which were further enhanced with increased angiogenesis and reduced fibrosis and inflammatory response. This therapeutic microporous hydrogel scaffold platform represents a new generation of microgel particles for MI therapy and will have broad applications in regenerative medicine and disease therapy.

The subject invention pertains to a decellularized stem cell sheet and compositions thereof with retained biological activity. The present invention further relates to the optimized method of producing the decellularized stem cell sheet and methods of using the decellularized stem cell sheet for the promotion of tissue repair in a subject.